Genomics Reporting Implementation Guide
2.0.0 - trial-use

This page is part of the Genetic Reporting Implementation Guide (v2.0.0: STU 2) based on FHIR R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Example Task: PGxRecEx02

Generated Narrative

Resource "PGxRecEx02"

Profile: Followup Recommendation

status: requested

intent: proposal

code: Consider alternative medication (LOINC#LA26421-0)

description: voriconazole - An alternative agent that is not dependent on CYP2C19 metabolism such as isavuconazole, liposomal amphotericin B, or posaconazole is recommended as primary therapy in lieu of voriconazole. A lower than standard dosage of voriconazole with careful therapeutic drug monitoring is another alternative. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/.

for: Patient/CGPatientExample01 " EVERYMAN"

reasonReference: Observation/TxImp02: Poor metabolizer